The small-to-medium biotech sector has experienced one of its most severe downturns in 2022, with funding drying up for scores of companies and many having to resort to cutting jobs and pipeline programs to survive. (Also see "Orchard and Zealand Join Growing List Of Biotechs On The Ropes" - Scrip, 31 March, 2022.)
How best to deal with the environment was the topic of discussion at the Jefferies Healthcare conference in London on 17 November for a panel of CEOs who have had...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?